About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
Article Date
April 9, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
January 15, 2026
citybiz – Questions & Answers with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
January 15, 2026
citybiz – Questions & Answers with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
February 10, 2026
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
February 10, 2026
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
